Hormone Therapy and Radiation for Intermediate Risk Prostate Cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of prostate cancer (adenocarcinoma).
- You need a testosterone level above 100 ng/dL and a PSA level above 0.2 ng/mL (but below 20 for this study).
- Your cancer should be a specific risk level: Gleason score 3+4 (with PSA below 20) or Gleason 3+3 (with PSA between 10 and 20).
- You must be able to swallow pills and willing to take daily medication if you are in the experimental group.
- You should not have had any prior treatment for prostate cancer with surgery or radiation directed to the prostate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding hormone therapy (ADT) to stereotactic body radiation therapy (SBRT) works better than SBRT alone for men with a specific type of prostate cancer called 'unfavorable intermediate risk.' The goal is to see if the combination helps control the cancer better.
This trial tests combining radiation therapy with two hormone-blocking drugs (darolutamide and degarelix) to treat intermediate-risk prostate cancer. The goal is to see if this combination is more effective and safe than radiation alone.
This trial studies a more sped-up radiation schedule for men with certain local prostate cancers, given together with hormone therapy. It aims to keep cancer control while possibly reducing treatment time and making care easier.
This trial tests a new radiation approach for prostate cancer that has not spread. It combines different types of radiation with or without hormone therapy to see if this approach works better with fewer side effects.
This trial tests a new type of radiation therapy that is customized for each patient's prostate cancer. The radiation targets the tumor more precisely, which may help reduce side effects while treating the cancer effectively.
This trial tests combining hormone therapy with different types of radiation (including high-dose external beam and brachytherapy) for men with prostate cancer that has a higher chance of coming back. It aims to see if adding radiation to the lymph nodes helps control the cancer better.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.